Merck & Co., Inc. (MRK) — closed signal from October 1, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 30, 2025.
Predicted vs. what happened
What happened
Reached its target in 48 days.
The thesis — published October 1, 2025
Merck is a steady, dividend-paying healthcare name. European drugmakers rose after Pfizer struck a pricing deal, which helped the group, including Merck. Near-term price action looks a bit heated, so patience can help. Over the next 0-3 months, the idea is to buy on pullbacks rather than paying up, and avoid chasing quick run-ups before the company's Q3 updates.
Primary drivers
- Healthcare stocks climbed after Pfizer reached a drug pricing deal in Europe
- Shares have been firm, and the dividend adds steady income with lower swings
- Blockbuster cancer drug Keytruda and a strong vaccine lineup anchor reliable sales
- Prefer buying on down days rather than paying up after quick, heated run-ups
How it played out
MRK: target reached in 48 days
Lyra published MRK at $85.39 on 2025-10-01 with 12% expected growth over a short-term window. The thesis pointed to healthcare stocks rising after Pfizer reached a drug pricing deal in Europe, Merck's dividend profile, Keytruda, its vaccine lineup, and a preference for buying pullbacks instead of chasing quick run-ups.
Inside the window, MRK reached the $94.83 target in 48 days. The peak was $107.59 on 2025-12-29, with a 26% gain at the high. The stock ended the window at $106.06. The published thesis played out, and price moved well past the target before the window closed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.